Welcome to the e-CCO Library!

P512: Vedolizumab is effective in the prevention and treatment of postoperative recurrence in patients with Crohn´s disease
Year: 2022
Source: ECCO'22
Authors: Kadleckova, B.(1);Podmanicky, D.(2);Lipovska, A.(1);Zelinkova, Z.(1);
Created: Friday, 11 February 2022, 3:56 PM
P513 has been withdrawn
Year: 2020
Source:

ECCO'20 Vienna

Created: Thursday, 30 January 2020, 10:12 AM
P513: Assessment of quality indicators in The Swedish Inflammatory Bowel Disease Registry (SWIBREG) for Crohn’s Disease treated with biological therapies
Year: 2021
Source: ECCO'21 Virtual
Authors: Xu, C.(1);Byman, V.(2);Hossain, J.(2);Storlåhls, A.(2);Hedin, C.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P513: Early initiation of anti-TNF is associated with favourable long-term outcome in Crohn’s disease: Ten-year follow-up data from the Swiss IBD cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Frei1, N. Fournier2, J. Zeitz3, M. Scharl1, B. Morell1, T. Greuter1, P. Schreiner1, B. Misselwitz1, E. Safroneeva4, A. Schoepfer5, S.R. Vavricka6, G. Rogler1, L. Biedermann on behalf of the Swiss IBD Cohort Study Group7*

Created: Thursday, 21 February 2019, 9:14 AM
P513: Managing IBD patients on adalimumab based on trough levels and antibodies
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Parisi I., Atherton R., McCartney S., Vega R., Mehta S., Whitley L., Kabir M., Kiparissi F., Bloom S.

Created: Wednesday, 20 February 2019, 10:36 AM
P513: Performance of a rapid test for adalimumab monitoring vs. conventional ELISA in a routine laboratory setting
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Van Stappen*1, B. H. Roovers2, F. van Deurzen2, A. J. van Vuuren2

Created: Friday, 22 February 2019, 9:41 AM
P513: Prospective study on patients' satisfaction and impact on quality of life of corticosteroid therapy in patients with Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Navarro Llavat, M.(1)*;García-Bosch, O.(1);Castro-Poceiro, J.(1);Bargalló García, A.(1);Ruiz Arroyo , D.(1);Navas Bravo , Y.(1);Erice Muñoz, E.(1);Barquero Declara, D.(1);Mata Bilbao, A.(1);Martín Llahí , M.(1);Ariza Solé, X.(1);Hernández Ballesteros, C.(1);Juan Juan , A.(1);Bustamante Robles, K.(1);Berbel Comas, C.(1);Blasco Pelicano, A.(1);Albareda Riera, M.(2);Domènech Morral , E.(3);
Created: Friday, 14 July 2023, 11:05 AM
P513: Treatment persistence in bio-naive patients with long-standing Crohn's disease treated with first-line biologics: real-life data from a Croatian tertiary center.
Year: 2022
Source: ECCO'22
Authors: Biscanin, A.(1);Tomasic, V.(1);Babic, F.(2);Dorosulic, Z.(1);Kralj, D.(1);Cacic, P.(1);Ogresta, D.(1);Hrabar, D.(1);
Created: Friday, 11 February 2022, 3:56 PM
P514 Does faecal diversion induce clinical response for Crohn’s disease of the colorectum?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Lightner1, H. Buhulaigah2, K. Zaghiyan2, P. Vaidya1, M. Regueiro1, P. Fleshner2

Created: Thursday, 30 January 2020, 10:12 AM
P514: Combination treatment with vedolizumab and anti-TNF-α in inflammatory bowel disease: safety data
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Buer L.*1,2, Høivik M.L.1, Medhus A.W.1, Moum B.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P514: Factors affecting clinical and endoscopic outcomes of placebo arm in trials of biologics and small-molecule drugs in ulcerative colitis: A meta-analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

F.S. Macaluso1*, M. Maida2, S. Renna1, M. Ventimiglia1, M. Cottone1, A. Orlando1

Created: Thursday, 21 February 2019, 9:14 AM
P514: Health Care Transition outcomes in inflammatory bowel disease: an international Delphi study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. van den Brink1, M. van Gaalen1, L. de Ridder1, J. Escher*1, J. van der Woude2

Created: Friday, 22 February 2019, 9:41 AM
P514: Influence of the frequency of glucocorticosteroid therapy courses on the hormonal resistance in patients with ulcerative colitis.
Year: 2021
Source: ECCO'21 Virtual
Authors: Knyazev, O.(1,2,3);Tishaeva, I.(2);Kagramanova, A.(1);Shkurko, T.(3);Veselov, A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P514: Optimising response to infliximab in the management of perianal Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: SHAH , R.(1);Anandbaskaran , S.(1);Hart , A.(1);Tozer , P.(1);
Created: Friday, 11 February 2022, 3:56 PM
P514: Serum levels of Klotho in inflammatory bowel disease: an exploratory study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hernandez-Camba, A.(1,2);Rodriguez-Jimenez, J.(1)*;Carrillo Palau, M.(3);Ramos Lopez, L.(3);Perez-Mendez , L.(4,5);Martin-Nuñez , E.(6);Alonso, I.(3);Vela, M.(1);Hernandez Alverez Builla, N.(3);Arranz, L.(1);Hernandez, A.(3);Ferraz Amaro, I.(7);Navarro‐Gonzalez, J.F.(6,8,9);
Created: Friday, 14 July 2023, 11:05 AM
P515 Comparability of upadacitinib pharmacokinetics in Japanese and non-Japanese subjects with ulcerative colitis with the extended-release formulation
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Stodtmann1, A. Friedel1, W. Zhou2, M.E. MOHAMED3

Created: Thursday, 30 January 2020, 10:12 AM
P515: A 12-week tailored physical training program including dietary advice in children with Inflammatory Bowel Disease: a randomized crossover trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Scheffers, L.(1);van den Berg, L.E.(1);Pijnenburg, M.W.(2);Utens, E.M.(3);Dieleman, G.C.(3);van der Ploeg , A.T.(4);Helbing, W.A.(5);Escher, J.C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P515: Costs associated with the management of refractory complex perianal fistulas in patients with Crohn's disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. D. Martín-Arranz*1, I. Pascual Migueláñez1, J. L. Marijuán1

Created: Friday, 22 February 2019, 9:41 AM
P515: Evaluation of treatment persistence of vedolizumab among Finnish inflammatory bowel disease patients in real-life clinical practice (FINVEDO)
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ylisaukko-oja T.1,2,3, Eberl A.*4, Aaltonen J.1, Nuutinen H.5, Blomster T.6, Jussila A.7, Pajala M.8, Jokelainen J.2,3, Herrala S.3, Tamminen K.1, Sipponen T.4

Created: Wednesday, 20 February 2019, 10:36 AM
P515: Inflammatory bowel disease and malignancy – the outcome of patients with malignancy diagnosed before IBD diagnosis or IBD-targeted therapy
Year: 2022
Source: ECCO'22
Authors: Shani, U.(1);Klang, E.(2);Ungar, B.(3);Ben-Horin, S.(3);Kopylov, U.(3);
Created: Friday, 11 February 2022, 3:56 PM